Tessa Romero
Stock Analyst at JP Morgan
(4.28)
# 443
Out of 5,042 analysts
64
Total ratings
48%
Success rate
22.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $34 → $33 | $22.02 | +49.86% | 10 | Sep 29, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $2.63 | - | 5 | Sep 16, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $40 → $30 | $15.18 | +97.63% | 10 | Aug 19, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $10 → $9 | $17.12 | -47.43% | 6 | Jul 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $68 → $55 | $16.60 | +231.33% | 7 | Jun 18, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $71 → $53 | $57.83 | -8.35% | 5 | Jun 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Overweight | $16 → $10 | $9.23 | +8.34% | 2 | May 30, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $21.85 | +73.91% | 1 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $17.85 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $29.68 | +4.45% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $11.98 | +142.07% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $46 | $43.33 | +6.16% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $40.76 | +34.94% | 2 | Apr 25, 2023 |
ACADIA Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $34 → $33
Current: $22.02
Upside: +49.86%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $2.63
Upside: -
Edgewise Therapeutics
Aug 19, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $15.18
Upside: +97.63%
Dyne Therapeutics
Jul 15, 2025
Maintains: Neutral
Price Target: $10 → $9
Current: $17.12
Upside: -47.43%
Biohaven
Jun 18, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $16.60
Upside: +231.33%
Cytokinetics
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $57.83
Upside: -8.35%
Lexeo Therapeutics
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $9.23
Upside: +8.34%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $21.85
Upside: +73.91%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $17.85
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $29.68
Upside: +4.45%
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $11.98
Upside: +142.07%
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $43.33
Upside: +6.16%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $40.76
Upside: +34.94%